Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Regeneron's experimental drug for myasthenia gravis, cemdisiran, has shown promising results in a Phase III trial and the company is aiming to file for FDA approval by 2026. Pharmaceutical spending in China has reached record levels, with more than $48 billion spent in the first half of the year. Former FDA Commissioner Scott Gottlieb has raised concerns about the US losing its edge in biopharma innovation to China. Additionally, a drug program for a rare neurodegenerative disorder has been discontinued by Amylyx, while pharma companies are increasingly focusing on scientific research and partnerships. Lilly's obesity pill is heading to the FDA for approval, AbbVie is investing in psychedelics, and HHS has announced more changes in the industry. The pharmaceutical landscape is rapidly evolving with new developments and challenges arising.Pharma CEOs are facing increasing pressure amid political turmoil and public distrust over drug pricing. The industry spent over $48 billion in China in the first half of the year, with expectations of increased deal volume in the future. Legal experts are working to determine ownership rights of AI creations in biotech. Obesity treatments are being compared for effectiveness, while biotech companies are making strides in AI-driven manufacturing. Job opportunities in gene therapy and biostatistics are available.

Support the show

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Lilly's new oral obesity drug is progressing towards FDA approval in 2025 after positive results from the second phase III trial for Orfoglipron. Analysts are optimistic about the potential for a "double-digit billion dollar opportunity" due to a manufacturing advantage.Arginex is looking to expand the label for Vyvgart in myasthenia gravis, while drugmakers are seeing success in AI-driven manufacturing. The White House has denied rumors of a potential ban on COVID-19 vaccines, as the pharmaceutical industry continues to innovate and adapt to challenges.With ongoing developments in scientific research and drug development, the industry remains at the forefront of innovation.

Support the show

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie has acquired Gilgamesh Pharmaceuticals for $1.2 billion, focusing on neurology and depression treatments. This move follows AbbVie's previous failure with Emraclidine in schizophrenia treatment. The biotech industry's IPO stalemate appears to be ending, with Lb Pharma planning an IPO to fund a phase III-ready schizophrenia asset. The FDA has pulled Valneva's chikungunya shot from the market due to safety concerns, and several obesity drugs have failed to make it to market. Meanwhile, Arnatar is working on advancing RNA therapies beyond silencing.In other news, the disappointment of oral obesity therapies is discussed, with Novo emerging as a leader in the field. Trials for Eli Lilly's Orforglipron and Viking Therapeutics' VK2735 were underwhelming, leading to increased interest in weight loss pills in low- and middle-income countries. Capricor Therapeutics plans to fight FDA rejection of its DMD cardiomyopathy treatment, while a study in JAMA contradicts claims of corruption in vaccine advisory committees. Updates on cancer, cell and gene therapy are also provided.Stay tuned for more updates and feel free to suggest topics for future coverage.

Support the show

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##New drug approval for rare genetic disorderToday, the FDA announced the approval of a new drug for a rare genetic disorder that affects approximately 1 in every 50,000 people. This drug has shown promising results in clinical trials, with patients experiencing significant improvements in their symptoms. This approval is a major milestone for the company and for patients who have been waiting for a treatment for this debilitating condition.##Positive results from Phase 3 clinical trialIn other news, a pharmaceutical company has reported positive results from a Phase 3 clinical trial for a new cancer treatment. The trial showed that the treatment was effective in shrinking tumors and improving survival rates in patients with advanced cancer. This is great news for the company and for patients who are in need of new treatment options.##Collaboration between two biotech companiesTwo biotech companies have announced a collaboration to develop a new treatment for a common autoimmune disease. This collaboration brings together the expertise of both companies and has the potential to lead to significant advancements in the field of autoimmune disease treatments. This partnership is a great example of how collaboration between companies can lead to innovative new treatments for patients.##FDA warning about counterfeit drugsThe FDA has issued a warning about counterfeit drugs that are being sold online. These counterfeit drugs may contain harmful ingredients or may not be effective in treating the conditions they are intended for. It is important for consumers to be cautious when purchasing medications online and to only buy from reputable sources. The FDA is working to crack down on the sale of counterfeit drugs and protect consumers from potential harm.##Drug pricing controversyThere has been controversy surrounding the pricing of a new drug that was recently approved by the FDA. The high cost of the drug has raised concerns about access to treatment for patients who may not be able to afford it. The pharmaceutical company has defended the pricing of the drug, citing the high cost of research and development. This controversy highlights the ongoing debate over drug pricing and access to affordable healthcare.##Investment in gene editing technologyA biotech company has announced a major investment in gene editing technology, with the goal of developing new treatments for genetic disorders. Gene editing technology has the potential to revolutionize the field of medicine by allowing scientists to make precise changes to DNA. This investment represents a significant step forward in the development of gene editing therapies and could lead to groundbreaking new treatments for patients with genetic disorders.##That's all for today's episode. Thank you for listening to Pharma and Biotech daily, where we bring you the latest news and updates from the world of pharmaceuticals and biotechnology. Stay tuned for more episodes coming soon.

Support the show

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. HHS employees have accused RFK Jr. of spreading public mistrust against the CDC after a shooting at their headquarters. They have asked him to stop spreading health misinformation, especially about vaccines and infectious diseases. In other news, Johnson & Johnson has added $2 billion to their US manufacturing commitment amid Trump's tariff threats. Regeneron's Eylea HD decisions have been delayed, and Stealth Biotherapeutics' rejected Barth drug is returning to the FDA for review. Fedegari is now a one-stop solution provider for the pharmaceutical industry, offering highly customized solutions for sterile drug production. Additionally, the American pharma industry is facing challenges with tariffs and policy changes. Several upcoming webinars and job opportunities in the pharmaceutical industry are also highlighted in the newsletter.

Support the show

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA is pushing new guidelines for cancer trials, recommending overall survival as a primary endpoint. Capricor Therapeutics is asking the FDA to reconsider their rejection of a treatment for DMD cardiomyopathy with the return of Vinay Prasad. Rocket Pharmaceuticals' phase II trial has resumed after a patient death, and the Trump administration's tariffs and drug pricing policies are causing confusion in the pharmaceutical industry. Fedegari is now offering customized solutions for the bio/pharmaceutical industry. The American Academy of Pediatrics is recommending the COVID-19 vaccine for kids, and there are updates on various biotech developments. Opinion pieces discuss drug pricing and the viability of high-dose peptides.The American pharmaceutical industry has lost the trust of the people, with many viewing them as the 'bad guys' despite producing drugs in the U.S. for Americans. The industry faces challenges such as competition and changing regulations, with the Trump administration's trade policies adding to the confusion. Some companies are taking a platform strategy approach to drug development, using one molecule to target multiple diseases. Despite these challenges, there are opportunities for innovation and growth in the industry. Additionally, conflicts of interest in vaccine committees have been decreasing, and companies are making strategic moves such as forming partnerships and restructuring to adapt to the changing landscape. The industry continues to navigate uncertainty and seek ways to improve drug development and access for patients.

Support the show

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Viking Therapeutics' oral obesity pill, VK2735, achieved over 12% weight loss in a clinical trial, causing their stock to plummet due to safety concerns. The pending approval of oral Wegovy has also brought attention to high-dose peptides.## Meanwhile, leaked information reveals a proposed overhaul of vaccine strategies and access to novel therapies. The FDA rejected PTC Therapeutics' drug for Friedreich's ataxia, and Novo Nordisk reassured investors of their capacity to supply oral semaglutide. Fedegari now offers customized solutions for the pharmaceutical industry, and Vantai is in talks with Halda for a potential proteomics partnership. ## Other news includes conflicts of interest in vaccine committees declining, RegenxBio facing a delay in their gene therapy approval, and Genentech ending a partnership with Adaptive Biotechnologies. Kriya raises $313 million for gene therapy, Merck KGaA invests in RNA-targeting technology, and Novo Nordisk receives approval for Wegovy.

Support the show

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo Nordisk's drug Wegovy has received approval for label expansion, potentially boosting its market performance. Tonix has also secured approval for a new fibromyalgia medication. Additionally, Novo has teamed up with GoodRx to provide lower prices for its drugs. Merck KGaA has made a significant investment of $2 billion in RNA-targeting technology through a collaboration with Skyhawk Therapeutics. On the sterilization front, Fedegari now offers tailored solutions for the pharmaceutical sector. In other updates, Pfizer's sickle cell therapy did not succeed in Phase III trials, while gene therapy company Kriya has raised an impressive $313 million. Kennedy has shown support for mRNA vaccines in cancer treatment. Bausch Health has closed a facility, Precigen has received FDA approval for an immunotherapy drug, and Eli Lilly has partnered with Superluminal in the obesity pipeline. Stay tuned for more industry news and developments.

Support the show

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Eli Lilly plans to raise drug prices in Europe in response to Trump's Most Favored Nation policy. RFK Jr. has expressed support for mRNA cancer vaccines after cutting mRNA BARDA contracts. Precigen wins FDA approval for an immunotherapy for recurrent respiratory papillomatosis, while Kennedy revives a childhood vaccine safety group and suggests mRNA vaccines could be effective for cancer. Genscript announces a new era of innovation, Bausch Health closes a California site, and Eli Lilly partners with Superluminal for obesity treatments. Trump delays tariffs, and upcoming webinars focus on AI in research, integrated supply chain strategies, and data lakes. Job opportunities include positions at Utro Biopharma, BioMarin Pharmaceutical, and AbbVie.

Support the show

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Eli Lilly has invested $1.3 billion in a partnership with Superluminal, an AI/ML startup focusing on endocrine and cardiometabolic diseases to develop new small molecule obesity medications. Schrodinger has discontinued the development of an early-stage blood cancer drug after two patient deaths. Trump has delayed pharma tariffs citing other priorities. RFK Jr. has been criticized for canceling Barda contracts related to mRNA vaccine research, leading to more vaccine misinformation. Genscript announces a new era of innovation and trust. Other news includes Vedanta downsizing, Abata shutting down.

Support the show